Le rôle du mécanisme RANK/RANKL/OPG dans la perte osseuse : nouvelles perspectives

Viser le ligand RANK augmente la densité minérale osseuse chez les femmes ménopausées : résultats d’essais de phase 3

Conférencière : Alexandra Papaioannou, M.D., M.Sc., FRCPC, Professeure, Directrice du département de médecine, Université McMaster, Gériatre, Hamilton Health Sciences Centre, Hamilton, ON.

Le rôle du mécanisme RANK/RANKL/OPG dans la perte osseuse : nouvelles perspectives

La biologie de l’os et le rôle du mécanisme RANK/RANKL/OPG

Conférencier : Robert G. Josse, M.D., Division d’endocrinologie et du métabolisme, Hôpital St. Michael’s; professeur de médecine, Université de Toronto, Toronto, ON.

 

The Role of RANK/RANKL/OPG Pathway in Bone Loss: New Insights

Targeting RANK Ligand Increases Bone Mineral Density in Postmenopausal Women: Results from Phase 3 Trials

Speaker: Alexandra Papaioannou, MD, MSc, FRCPC, Professor, Department of Medicine Director, Division of Geriatric Medicine, McMaster University, Geriatrician, Hamilton Health Sciences Centre, Hamilton, ON.

 

The Role of RANK/RANKL/OPG Pathway in Bone Loss: New Insights

Bone Biology and the Role of RANK/RANKL/OPG Pathway

Speaker: Robert G. Josse, MD, Division of Endocrinology & Metabolism, St. Michael’s Hospital; Professor of Medicine, University of Toronto, Toronto, ON.

L. Giangregorio, PhD, Lyndhurst Centre, Toronto Rehabilitation Institute, Toronto, ON.
A. Papaioannou, MD, Department of Medicine, McMaster University, Hamilton, ON.
J.D. Adachi, MD, Department of Medicine, McMaster University, Hamilton, ON.

The most effective bone-building treatment may turn out to be a modified form of parathyroid hormone. Researchers report that a peptide formed from the first 34 amino acids of parathyroid hormone is effective in preventing fractures in post-menopausal women. Previously, it was known that injections of parathyroid hormone, or its amino terminal fragment (parathyroid hormone 1-34), increased bone formation and bone mass, but their effects on fractures were unknown.

Christine Oyugi, BSc
Assistant Managing Editor,
Geriatrics & Aging

Lilia Malkin, BSc

A fracture is often the first clinical sign of osteoporosis (OP), the silent disease of skeletal fragility characterized by decreased bone mass and deterioration of bone tissue that results in an increased vulnerability to fractures.

Rhonda Witte, BSc